ATE519756T1 - Prophylaktikum bzw. therapeutikum für altersbedingte makuladegeneration - Google Patents

Prophylaktikum bzw. therapeutikum für altersbedingte makuladegeneration

Info

Publication number
ATE519756T1
ATE519756T1 AT08764549T AT08764549T ATE519756T1 AT E519756 T1 ATE519756 T1 AT E519756T1 AT 08764549 T AT08764549 T AT 08764549T AT 08764549 T AT08764549 T AT 08764549T AT E519756 T1 ATE519756 T1 AT E519756T1
Authority
AT
Austria
Prior art keywords
prophylactic
age
macular degeneration
related macular
therapeutic
Prior art date
Application number
AT08764549T
Other languages
English (en)
Inventor
Shin-Ichiro Hirai
Atsushi Yoshida
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE519756T1 publication Critical patent/ATE519756T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D293/00—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms
    • C07D293/10—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D293/12—Selenazoles; Hydrogenated selenazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT08764549T 2007-05-25 2008-05-23 Prophylaktikum bzw. therapeutikum für altersbedingte makuladegeneration ATE519756T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007138519 2007-05-25
PCT/JP2008/059503 WO2008146721A1 (ja) 2007-05-25 2008-05-23 加齢黄斑変性の予防又は治療剤

Publications (1)

Publication Number Publication Date
ATE519756T1 true ATE519756T1 (de) 2011-08-15

Family

ID=40074974

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08764549T ATE519756T1 (de) 2007-05-25 2008-05-23 Prophylaktikum bzw. therapeutikum für altersbedingte makuladegeneration

Country Status (10)

Country Link
US (1) US8309612B2 (de)
EP (1) EP2163548B1 (de)
JP (1) JP5314931B2 (de)
KR (1) KR20100016140A (de)
CN (1) CN101679328B (de)
AT (1) ATE519756T1 (de)
CA (1) CA2686560A1 (de)
ES (1) ES2370751T3 (de)
RU (1) RU2460526C2 (de)
WO (1) WO2008146721A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1884234E (pt) 2005-05-17 2012-07-26 Santen Pharmaceutical Co Ltd Agente profiláctico ou terapêutico para distúrbio corneano e conjuntival
WO2009107759A1 (ja) * 2008-02-28 2009-09-03 参天製薬株式会社 視神経障害を伴う眼疾患の予防又は治療剤
SI3708178T1 (sl) * 2009-08-24 2024-01-31 Stealth Biotherapeutics Inc. Peptid za uporabo pri preprečevanju ali zdravljenju degeneracije makule
DK2493296T3 (en) 2009-10-30 2019-04-15 Retrotope Inc REMOVAL OF OXIDATIVE STRESS STATES WITH PUFA DERIVATIVES
US20140018402A1 (en) * 2011-03-30 2014-01-16 Catholic University Industry Academic Cooperation Foundation Pharmaceutical composition for preventing or treating macular degeneration
US10154983B2 (en) 2011-04-26 2018-12-18 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating PUFAs
US10058522B2 (en) 2011-04-26 2018-08-28 Retrotope, Inc. Oxidative retinal diseases
KR102020579B1 (ko) 2011-04-26 2019-09-10 레트로토프 인코포레이티드 에너지 프로세싱 손상 장애 및 미토콘드리아 결함
WO2012148929A2 (en) 2011-04-26 2012-11-01 Retrotope, Inc. Disorders implicating pufa oxidation
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
WO2017091279A1 (en) 2015-11-23 2017-06-01 Retrotope, Inc. Site-specific isotopic labeling of 1, 4-diene systems
GB201616158D0 (en) * 2016-09-22 2016-11-09 Provost Fellows Foundation Scholars & The Other Members Of Board Of The College Of The Holy & Unidv Age-related macular degeneration
WO2020028923A2 (en) * 2018-08-02 2020-02-06 Curelab Oncology, Inc. Compositions and methods relating to p62 for the treatment and prophylaxis of age-related macular degeneration
EP4107163A4 (de) 2020-02-21 2024-06-19 Retrotope, Inc. Verfahren zur isotopenmodifizierung von mehrfach ungesättigten fettsäuren und deren derivaten
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
US11491130B2 (en) 2021-02-05 2022-11-08 Retrotope, Inc. Methods of treating amyotrophic lateral sclerosis
WO2026073143A1 (en) * 2024-09-27 2026-04-02 Sound Pharmaceuticals Inc. Cochlear implant eluting ebselen for treating hearing loss
CN120093774A (zh) * 2025-03-20 2025-06-06 中国科学院杭州医学研究所 Capilliposide A在制备防治年龄相关性黄斑变性的药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61257412A (ja) 1985-05-09 1986-11-14 Nippon Steel Corp 転炉排ガス処理装置のスカ−トシ−ル装置
DE3616923A1 (de) * 1986-05-20 1987-11-26 Nattermann A & Cie Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on
DE3620674A1 (de) * 1986-06-20 1987-12-23 Nattermann A & Cie Salbe zur behandlung von hauterkrankungen
US4778814A (en) 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of treating ocular allergy by topical application of a 2-substituted-1,2-benzisoselenazol-3(2H)-one
US6342510B1 (en) 1995-06-12 2002-01-29 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist
FR2740339B1 (fr) 1995-10-26 1997-12-05 Oreal Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
FR2757860B1 (fr) 1996-12-27 1999-04-23 Oxis International Sa Composes organoselenies cycliques, leur preparation et leurs utilisations, notamment therapeutiques
JP2001261555A (ja) 2000-03-17 2001-09-26 Dai Ichi Seiyaku Co Ltd 脳動脈中膜肥厚抑制剤
FR2815541B1 (fr) * 2000-10-24 2008-02-29 Lipha Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
WO2004069157A2 (en) 2003-01-17 2004-08-19 Ophthalmic Research Associates, Inc. Combinational use of long-acting and short-acting anti-histamines for ocular allergies
WO2004112796A1 (en) * 2003-06-20 2004-12-29 Alcon, Inc. Treatment of amd with combination of ingredients
JP2006104199A (ja) 2004-09-13 2006-04-20 Santen Pharmaceut Co Ltd 角結膜障害治療剤
PT1884234E (pt) 2005-05-17 2012-07-26 Santen Pharmaceutical Co Ltd Agente profiláctico ou terapêutico para distúrbio corneano e conjuntival
JP5087233B2 (ja) * 2005-05-17 2012-12-05 参天製薬株式会社 角結膜障害の予防または治療剤
WO2009107759A1 (ja) 2008-02-28 2009-09-03 参天製薬株式会社 視神経障害を伴う眼疾患の予防又は治療剤

Also Published As

Publication number Publication date
WO2008146721A1 (ja) 2008-12-04
JP2009007337A (ja) 2009-01-15
EP2163548A1 (de) 2010-03-17
CN101679328A (zh) 2010-03-24
CA2686560A1 (en) 2008-12-04
KR20100016140A (ko) 2010-02-12
JP5314931B2 (ja) 2013-10-16
EP2163548A4 (de) 2010-06-30
EP2163548B1 (de) 2011-08-10
ES2370751T3 (es) 2011-12-22
RU2460526C2 (ru) 2012-09-10
US8309612B2 (en) 2012-11-13
CN101679328B (zh) 2011-12-28
RU2009148288A (ru) 2011-06-27
US20100120873A1 (en) 2010-05-13

Similar Documents

Publication Publication Date Title
EP2163548A4 (de) Prophylaktikum bzw. therapeutikum für altersbedingte makuladegeneration
ZA202004764B (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
SG11202002640YA (en) Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
HK1258588A1 (zh) 用於治疗眼科疾病的化合物和制剂
IL276016B (en) Ocular formulations for administration of drug to the back of the eye
MX367897B (es) Derivados de piridazinona macrociclicos.
IL211448A (en) Use of bio-enhancers and/or photo-enhancers for preparing ophthalmic compositions comprising riboflavin or riboflavin phosphate for treating corneal ectasic disorders by corneal cross-linking
EP2663281A1 (de) Korneale freisetzung von vernetzungsmittel mittels iontophorese zur behandlung von keratokonus und zugehörige ophthalmische zusammensetzungen
EP2663561A1 (de) Neue heterocyclische derivate und ihre verwendung bei der behandlung von nervenerkrankungen
MY171920A (en) Prevention and treatment of ocular conditions
NZ704247A (en) Compositions and treatment for eye diseases and disorders
WO2011116020A3 (en) Ophthalmic formulations of cetirizine and methods of use
NZ727304A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
MX2012000539A (es) Regimen de rocio nasal de olopatadina para niños.
UA114705C2 (uk) Андрогенна композиція для лікування офтальмологічного захворювання
ECSP11010956A (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos
EP2148667A4 (de) Verwendung von cyclohexanhexol-derivaten bei der behandlung von augenerkrankungen
NZ704178A (en) Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
MY178169A (en) Topical ophthalmic peptide formulation
ZA202003944B (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
CA2909622C (en) Quinone based nitric oxide donating compounds for ophthalmic use
ECSP067039A (es) Piridin-4-il-etinil-imidazoles y pirazoles como antagonistas del receptor mglu5
CA2863110A1 (en) 1,2- pyridazine, 1,6- pyridazine or pyrimidine - benzamide derivatives as gpbar1 modulators
HK40033459A (en) Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties